Fibrinogen 91mg powder for solution for sealant vials
Fibrinogen concentrate (human) is a hematological agent.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Fibrinogen human
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 2 · 1963–2026
Showing the 50 most relevant studies, sorted by most relevant.
Razi B, Eslami M, Hatami A, et al.
2026
- Lipoproteins
- Fibrinogen
- Blood Component Removal
Behera S, Sahoo N, Sahu S
2026
Yi Zhang, Guoliang Xiao
Cancer Management and Research, 2019
Nicholas JC, Alkis T, Bis JC, et al.
2026
- Vascular Diseases
- Inflammation
- Fibrinogen
BackgroundFibrinogen is a critical coagulation factor that plays an essential role in thrombosis and is elevated in individuals with chronic inflammation.ObjectivesHere, we used fibrinogen as a representative quantitative measure of procoagulant risk and evaluated metabolites associated with fibrinogen levels using nontargeted plasma metabolomics profiling (Broad and Metabolon platforms).MethodsOur analysis included 10 533 individuals across 6 United States-based cohorts representing diverse population groups. The cross-sectional relationship between each of the 789 metabolites tested and plasma fibrinogen concentration was assessed after adjustment for relevant covariates, including age, cohort-reported sex, body mass index, and circulating lipoprotein levels.ResultsMeta-analysis of per-cohort results revealed 270 metabolites significantly associated with fibrinogen levels (false discovery rate-adjusted P value ConclusionThese findings contribute to the growing list of metabolite biomarkers that may influence coagulation and inflammation pathways and, thereby, vascular risk.
Abstract licence: CC BY-NC-ND
A. Ducloy‐Bouthors, F-J Mercier, J. Grouin, et al.
BJOG: An International Journal of Obstetrics & Gynaecology, 2021
Jun Wang, M. Sanmamed, I. Datar, et al.
Cell, 2018
Mario Merlini, Victoria A. Rafalski, Pamela E. Rios Coronado, et al.
Neuron, 2019
Rui Vilar, R. Fish, A. Casini, et al.
Haematologica, 2020
Bang YJ, Oh CS, Lee DK, et al.
2026
- Afibrinogenemia
- Fibrinogen
- Factor VIII
Dong-Wook Lee, Jaehak Jung, Seul-ah Park, et al.
Scientific Reports, 2024
Recent studies have indicated potential health risks associated with microplastics (MPs) exposure, including alterations in blood coagulation homeostasis. This cross-sectional study aimed to quantitatively examine MPs in human blood and assess their association with coagulation markers. We recruited 36 healthy adults, collected whole blood samples, and analyzed MPs using Fourier-transform infrared (µ-FTIR) spectroscopy. Lifestyle factors related to MP exposure were assessed, such as the use of plastic food containers. Coagulation and inflammatory markers in blood samples were analyzed, including C-reactive protein, prothrombin time, activated partial prothrombin time (aPTT), antithrombin III, platelet count, erythrocyte sedimentation rate, and fibrinogen. MPs were detected in 88.9% of the participants, with a mean concentration of 4.2 MPs/mL. The predominant types of plastics identified were polystyrene and polypropylene. MPs were significantly higher in participants with a greater use of plastic food containers. A high MP load in the blood (≥ 3 MPs/mL) was significantly correlated with increased aPTT, C-reactive protein, and fibrinogen. We identified MPs in human blood, their association with specific lifestyle factors, and significant alterations in coagulation markers. This underscores the need for strategies to reduce human exposure to MPs, particularly in relation to blood coagulation and potential cardiovascular risks.
Abstract licence: CC BY-NC-ND
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Fibrinogen (factor I) is a soluble plasma glycoprotein with a molecular weight of about 340 kDa.
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
[L41065]
It is also indicated for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency.
[L41065]
In combination with thrombin, it is used indicated as an adjunct to hemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical.
[L12936][L12939]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 91 interactions
ATC B02BB01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Fibrinogen human
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72